PR Newswire
LEXINGTON, Mass., Oct. 14, 2020
LEXINGTON, Mass.
,
Oct. 14, 2020
/PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that a Trial in Progress abstract for CI-8993, a first-in-class monoclonal anti-VISTA antibody, has been accepted for poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 35
th
Anniversary Annual Meeting, which will be held virtually from
November 9-14, 2020
.
Details of the poster session are as follows:
-
Title:
Phase 1 Study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies -
Author:
Melissa L. Johnson
, MD,
Sarah Cannon Research Institute
-
Date & Time:
Wednesday, November 11
th
, 2020 –
Saturday, November 14
th
, 2020 from
9:00 am
–
5:00 pm ET
-
Abstract ID:
743
Additional meeting information can be found on the SITC website at
www.sitcancer.org
. The poster presentation will also be available under “Events and Presentations” in the Investors section of the Company’s website at
www.curis.com
About Curis, Inc.
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma and in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/
1b
trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge
®
for the treatment of advanced basal cell carcinoma. For more information, visit Curis’ website at
www.curis.com
.
View original content to download multimedia:
http://www.prnewswire.com/news-releases/curis-announces-abstract-for-ci-8993-accepted-for-presentation-at-the-society-for-immunotherapy-of-cancers-sitc-35th-anniversary-annual-meeting-301152649.html
SOURCE Curis, Inc.
